Latest Methicillin-resistant Staphylococcus aureus Stories
Eravacycline's Competitive Advantages Include Activity Against Multidrug-Resistant Pathogens and Availability in Interchangeable IV and Oral Formulations, According to a New Report from Decision Resources BURLINGTON, Mass., April 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, Tetraphase Pharmaceuticals'...
AUSTIN, Texas, April 18, 2013 /PRNewswire/ --Savara Pharmaceuticals announced today that the first patient has started study drug treatment in a Phase 2 clinical trial evaluating the safety and efficacy of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients. AeroVanc is the first inhaled antibiotic being developed to address the growing population of MRSA lung-infected CF patients. Persistent...
Significant Mortality and Billions in Costs From Patient Infections Contracted by Improper Employee Hand Hygiene at U.S. Hospitals WASHINGTON, D.C. (PRWEB) April 16, 2013 IntelligentM today announced it has contracted with multiple hospitals for the use of its unique IntelligentM Smartband System, which combats improper hand hygiene that results in tens of thousands of annual deaths and billions of dollars in unnecessary costs to the U.S. hospital system. The current hand hygiene...
University of California - San Diego [ Watch The Video ] Engineers at the University of California, San Diego have invented a "nanosponge" capable of safely removing a broad class of dangerous toxins from the bloodstream – including toxins produced by MRSA, E. coli, poisonous snakes and bees. These nanosponges, which thus far have been studied in mice, can neutralize "pore-forming toxins," which destroy cells by poking holes in their cell membranes. Unlike other anti-toxin platforms...
Four-year Study Proves Antimicrobial Copper Metal Surfaces are Capable of Saving Patient Lives NEW YORK, April 9, 2013 /PRNewswire/ -- New research has revealed that the use of Antimicrobial Copper surfaces in hospital rooms can reduce the number of healthcare-acquired infections (HAIs) by 58% as compared to patients treated in Intensive Care Units with non-copper touch surfaces. In the United States, 1 out of every 20 hospital patients develops an HAI, resulting in an estimated...
AUSTIN, TX and TORONTO, March 20, 2013 /PRNewswire/ - Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections (ABSSSI) demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors). Barry Hafkin, MD, Chief Medical...
Largest TCA funding to date will support clinical trials of innovative antibiotic for cystic fibrosis patients SAN DIEGO, March 20, 2013 /PRNewswire/ -- Tech Coast Angels (TCA), the largest and most active angel network in the United States, announced that the network contributed $3.2 million to a Savara Pharmaceuticals Series B financing. This is the largest single funding ever raised by the TCA network. The TCA investment is part of a $16 million Series B generated through a...
AUSTIN, TX and TORONTO, March 13, 2013 /PRNewswire/ - Affinium Pharmaceuticals announced today the expansion of its leadership team with the appointment of two senior biotech and pharmaceutical executives to its leadership team: Ed Mascioli, M.D. is appointed Chief Executive Officer (CEO), and Mr. Robert (Bob) Radie is appointed to the Board of Directors. Dr. Mascioli is an experienced pharmaceutical and venture executive, and held prior positions as a senior executive at...
Company Responds to Call from World Economic Forum Describing Antimicrobial Resistance as Greatest Threat to Global Health WALTHAM, Mass., March 13, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR) is pleased to announce the launch today of a new campaign, Test Target Treat(TM), at the 9(th) Annual International Symposium on Antimicrobial Agents and Resistance. The campaign is designed to combat antimicrobial resistance by educating healthcare professionals on the importance of using...
Antimicrobial Copper Products in Hospitals Should Be Considered as a Response to CDC's Latest Warning on Lethal Bacteria NEW YORK, March 12, 2013 /PRNewswire/ -- Deadly bacterial infections are on the rise in American hospitals, as antibiotics are being overcome by germs known as carbapenem-resistant Enterobacteriaceae (CRE). While many antibiotics have failed to treat bacteria such as CRE, Antimicrobial Copper has been proven to continuously kill greater than 99.9% of bacteria* that...
